NO972732L - Karsinombehandling - Google Patents

Karsinombehandling

Info

Publication number
NO972732L
NO972732L NO972732A NO972732A NO972732L NO 972732 L NO972732 L NO 972732L NO 972732 A NO972732 A NO 972732A NO 972732 A NO972732 A NO 972732A NO 972732 L NO972732 L NO 972732L
Authority
NO
Norway
Prior art keywords
karsinombehandling
carcinomas
inducer
prevention
conjunction
Prior art date
Application number
NO972732A
Other languages
English (en)
Other versions
NO972732D0 (no
NO318587B1 (no
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of NO972732D0 publication Critical patent/NO972732D0/no
Publication of NO972732L publication Critical patent/NO972732L/no
Publication of NO318587B1 publication Critical patent/NO318587B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19972732A 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose NO318587B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (3)

Publication Number Publication Date
NO972732D0 NO972732D0 (no) 1997-06-13
NO972732L true NO972732L (no) 1997-06-13
NO318587B1 NO318587B1 (no) 2005-04-11

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972732A NO318587B1 (no) 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose

Country Status (12)

Country Link
EP (1) EP0806963B1 (no)
JP (1) JP4076230B2 (no)
AT (1) ATE203676T1 (no)
AU (1) AU691996B2 (no)
CA (1) CA2207779C (no)
DE (1) DE69522012T2 (no)
FI (1) FI118918B (no)
GB (1) GB9425060D0 (no)
MX (1) MX9704372A (no)
NO (1) NO318587B1 (no)
NZ (1) NZ296161A (no)
WO (1) WO1996018413A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1974747B1 (en) 1998-08-11 2012-06-27 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044305A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
CN101325970B (zh) 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
EP2419531B1 (en) 2009-04-18 2016-09-07 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2585153C2 (ru) 2010-12-02 2016-05-27 Аимм Терапьютикс Б.В. Средства и способы получения высокоаффинных антител
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP3099709B1 (en) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
NO972732D0 (no) 1997-06-13
DE69522012T2 (de) 2002-04-25
JP4076230B2 (ja) 2008-04-16
FI972484A0 (fi) 1997-06-12
EP0806963A1 (en) 1997-11-19
JPH10510526A (ja) 1998-10-13
AU3988495A (en) 1996-07-03
EP0806963B1 (en) 2001-08-01
NO318587B1 (no) 2005-04-11
WO1996018413A1 (en) 1996-06-20
CA2207779C (en) 2009-10-06
GB9425060D0 (en) 1995-02-08
FI972484L (fi) 1997-06-12
NZ296161A (en) 2001-10-26
ATE203676T1 (de) 2001-08-15
MX9704372A (es) 1998-02-28
AU691996B2 (en) 1998-05-28
DE69522012D1 (de) 2001-09-06
FI118918B (fi) 2008-05-15
CA2207779A1 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
NO972732D0 (no) Karsinombehandling
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
TR28384A (tr) Flüoroalifatik -ve karboksil- iceren terminal gruplarina sahip polisilokzanlar, bunlarin hazirlanmasi, ve lifli malzemelerin muamelesinde kullanimlari.
NL8601053A (nl) Imidazochinolinen met antithrombogene en cardiotonische eigenschappen.
EP0492248A3 (en) Intumescent sheet, its manufacture and use
ES292314U (es) Un articulo sanitario
NO912625D0 (no) Betongstein belagt med kopolymerfilm, samt fremgangsmaate for fremstilling av betongsteinen.
RU95101375A (ru) Производные n-(3-аминопропил)-n-фенил-5,6,7,8-тетрагидронафталин-2-карбоксамида, их получение и применение в терапии
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
DE3766276D1 (de) Gegen abblaettern bestaendige polymerzusammensetzung, sowie beschichtung.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO902532L (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
HU910968D0 (en) New retinoids
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
FI88228C (fi) Dielektrisk resonatorkonstruktion
MX9700813A (es) Nuevos derivados 3-substituidos de 3h-2,3-benzodiazepina, su preparacion y su uso como medicamentos.
ZA972776B (en) 4-[(thien-2-yl)methyl]-imidazole analgesics
DE69108396D1 (de) Hohe kolloidale Kapazitätsekundärbatterie, Kolloidelektrolyt und dessen Verwendung, sowie deren Herstellungsverfahren.
ES2013025A6 (es) Un metodo para preparar 24r-escimnol.
ES8504419A1 (es) Procedimiento para la sensibilizacion al calor de dispersiones acuosas de polimero.
DE59106847D1 (de) Überzugsmittel sowie dessen Verwendung.
AU8136398A (en) Sheet aligning device and sheet treating device provided with the same
KR940018863U (ko) 온, 난방 장치를 구비한 식탁

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees